Home » Stocks » JNCE

Jounce Therapeutics, Inc. (JNCE)

Stock Price: $9.12 USD 1.36 (17.53%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $9.35 +0.23 (2.52%) Jan 15, 7:55 PM
Market Cap 363.45M
Revenue (ttm) n/a
Net Income (ttm) -101.98M
Shares Out 34.16M
EPS (ttm) -3.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $9.12
Previous Close $7.76
Change ($) 1.36
Change (%) 17.53%
Day's Open 7.74
Day's Range 7.90 - 9.22
Day's Volume 1,133,010
52-Week Range 2.91 - 10.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 2 days ago

These baby biotechs are itching to come out of their shells.

Other stocks mentioned: SURF
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...

Seeking Alpha - 2 weeks ago

Jounce is developing several novel immunotherapies that target T cells and macrophages. I am bearish on the success of Vopratelimab and JTX-8064 and neutral on the prospects of JTX-4014 and JT...

Zacks Investment Research - 3 weeks ago

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...

GlobeNewsWire - 2 months ago

-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce's PD-1 inhibitor, JTX-4014 -

GlobeNewsWire - 2 months ago

- Preclinical data highlight Jounce's approach to identif y potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064 -

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...

Seeking Alpha - 2 months ago

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020-

The Motley Fool - 2 months ago

The company announced disappointing news from a phase 2 study.

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies ...

The Motley Fool - 3 months ago

These biotechs have a long road ahead, but they just might deliver massive growth.

Other stocks mentioned: RUBY, SRNE
Seeking Alpha - 4 months ago

Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapi...

Zacks Investment Research - 4 months ago

Gilead (GILD) signs a deal with Jounce Therapeutics to exclusively license the latter's monoclonal antibody, JTX-1811.

Other stocks mentioned: GILD
24/7 Wall Street - 4 months ago

Jounce Therapeutics Inc. (NASDAQ: JNCE) made a massive gain on Tuesday after the company announced a licensing agreement with Gilead Sciences Inc.

Other stocks mentioned: GILD
Market Watch - 4 months ago

Shares of Gilead Sciences Inc. GILD, +2.28% were down 0.1% in premarket trading on Tuesday after the drugmaker announced an agreement to exclusively license Jounce Therapeutics Inc.

Other stocks mentioned: GILD
GlobeNewsWire - 4 months ago

  – Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody –

Seeking Alpha - 5 months ago

Jounce Therapeutics' (JNCE) CEO Rich Murray on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 -

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...

GlobeNewsWire - 6 months ago

- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells -

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...

The Motley Fool - 7 months ago

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Other stocks mentioned: AGIO, MRSN, STRO
GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...

Seeking Alpha - 8 months ago

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.

Seeking Alpha - 10 months ago

Jounce Therapeutics: An Attractive Immunotherapy Pick For 2020

Seeking Alpha - 11 months ago

Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System

GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...

Zacks Investment Research - 1 year ago

Is (JNCE) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

Slowing trade conflicts and rate cuts by the Federal Reserve boost the domestic economy. The trend is expected to continue in the next year.

Other stocks mentioned: AEGN, FBM, ICHR, SPAR
Zacks Investment Research - 1 year ago

Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.

Zacks Investment Research - 1 year ago

A section of the U.S. business community - the small business segment - seems optimistic about the future despite trade-related hiccups.

Other stocks mentioned: FBM, FRTA, HIBB, OESX
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Jounce Therapeutics, Inc. (JNCE).

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 2nd

Other stocks mentioned: GH, TGT, TNK
Zacks Investment Research - 1 year ago

Healthcare bounced back with an outperformance starting the fourth quarter.

Other stocks mentioned: BBC, CNCR, GNOM, IHF, IRWD, OSMT, SBIO, SEM
Seeking Alpha - 1 year ago

Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 28.89% and 19.48%, respectively, for the quarter ended September 2019.

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapi...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapie...

Seeking Alpha - 1 year ago

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019.

Seeking Alpha - 1 year ago

Jounce Therapeutics established updated deal with Celgene with the potential to earn up to $530 million in payments based on JTX-8064.

Benzinga - 1 year ago

Jounce Therapeutics Inc (NASDAQ: JNCE) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG), the latter of which has agr...

Other stocks mentioned: CELG
24/7 Wall Street - 1 year ago

Jounce Therapeutics Inc. (NASDAQ: JNCE) shares jumped on Wednesday after the company announced an update on its strategic collaboration with Celgene Corp.

About JNCE

Jounce Therapeutics, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and J... [Read more...]

Industry
Biotechnology
IPO Date
Jan 27, 2017
CEO
Richard Murray
Employees
129
Stock Exchange
NASDAQ
Ticker Symbol
JNCE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is 9.88, which is an increase of 8.33% from the latest price.

Price Target
$9.88
(8.33% upside)
Analyst Consensus: Buy